Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
7.14
+0.27 (3.93%)
Jun 3, 2026, 11:30 AM EDT - Market open
Artiva Biotherapeutics Employees
Artiva Biotherapeutics had 104 employees as of December 31, 2025. The number of employees increased by 15 or 16.85% compared to the previous year.
Employees
104
Change
15
Growth
16.85%
Revenue / Employee
n/a
Profits / Employee
-$837,212
Market Cap
346.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | 15 | 16.85% |
| Sep 30, 2025 | 106 | 24 | 29.27% |
| Jun 30, 2025 | 105 | 23 | 28.05% |
| Mar 31, 2025 | 96 | 15 | 18.52% |
| Dec 31, 2024 | 89 | 8 | 9.88% |
| Sep 30, 2024 | 82 | - | - |
| Jun 30, 2024 | 82 | - | - |
| Mar 31, 2024 | 81 | - | - |
| Dec 31, 2021 | 43 | 21 | 95.45% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Abeona Therapeutics | 226 |
| Lyell Immunopharma | 161 |
| Nautilus Biotechnology | 127 |
| Invivyd | 122 |
| Verastem | 102 |
| Neumora Therapeutics | 96 |
| Prelude Therapeutics | 79 |
ARTV News
- 6 days ago - Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 14 days ago - Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - GlobeNewsWire
- 15 days ago - Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - GlobeNewsWire
- 21 days ago - Artiva Biotherapeutics price target raised to $41 from $18 at Needham - TheFly
- 22 days ago - Artiva Biotherapeutics price target raised to $40 from $23 at Wedbush - TheFly
- 25 days ago - Artiva Biotherapeutics price target raised to $35 from $15 at H.C. Wainwright - TheFly
- 26 days ago - Artiva Biotherapeutics Earnings release: Q1 2026 - Filings
- 26 days ago - Artiva Biotherapeutics Quarterly report: Q1 2026 - Filings